The DOI matches its Crossref record; 73 of the 74 references it cites were found in a registry or an index.
Neurodegeneration in a Transgenic Mouse Model of Multiple System Atrophy Is Associated with Altered Expression of Oligodendroglial-Derived Neurotrophic Factors
Open accessAbstract
Multiple system atrophy (MSA) is a neurodegenerative disorder characterized by striatonigral degeneration and olivo-pontocerebellar atrophy. Neuronal degeneration is accompanied by primarily oligodendrocytic accumulation of α-synuclein (αsyn) as opposed to the neuronal inclusions more commonly found in other α-synucleinopathies such as Parkinson's disease. It is unclear how αsyn accumulation in oligodendrocytes may lead to the extensive neurodegeneration observed in MSA; we hypothesize that the altered expression of oligodendrocyte-derived neurotrophic factors by αsyn may be involved. In this context, the expression of a number neurotrophic factors reportedly expressed by oligodendrocytes [glial-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF), and insulin-like growth factor 1 (IGF-1), as well as basic fibroblast growth factor 2 (bFGF2), reportedly astrocyte derived] were examined in transgenic mouse models expressing human αsyn (hαsyn) under the control of either neuronal (PDGFβ or mThy1) or oligodendrocytic (MBP) promoters. Although protein levels of BDNF and IGF-1 were altered in all the αsyn transgenic mice regardless of promoter type, a specific decrease in GDNF protein expression was observed in the MBP-hαsyn transgenic mice. Intracerebroventricular infusion of GDNF improved behavioral deficits and ameliorated neurodegenerative pathology in the MBP-hαsyn transgenic mice. Consistent with the studies in the MBP-hαsyn transgenic mice, analysis of GDNF expression levels in human MSA samples demonstrated a decrease in the white frontal cortex and to a lesser degree in the cerebellum compared with controls. These results suggest a mechanism in which αsyn expression in oligodendrocytes impacts on the trophic support provided by these cells for neurons, perhaps contributing to neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The precise pathogenesis of MSA remains largely unknown, however, evidence from human postmortem cases and experimental models suggest that, in addition to GCIs, myelin degeneration, axonal damage, loss of neurotrophic support, neuronal loss, astrogliosis and microglial activation are pathological events seen in multiple regions of the central nervous system (CNS) [28, 56].”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [56]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Moreover, decreased neurotrophic support of oligodendroglia, as shown by reductions of glial derived neurotrophic factor expression levels in MSA tg mice and human MSA samples [56], furthers the idea that oligodendrocyte dysfunction is an early pathological event leading to secondary neurodegeneration related to retrograde axonal disease.”
From Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates (2017) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
Self-citationDirect brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
GDNF: a Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle
Henderson, C. E., PHILLIPS, H. S., Pollock, R. A., Davies, A. M., Lemeulle, C., Armanini, M. P., Simmons, L. C., Moffet, B., Vandlen, R. A., Koliatsos, V. E., et al. (1994) · Science · doi:10.1126/science.7973664 · Cited by 1,273
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Tu, P., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., & Lee, V. M. ‐. (1998) · Annals of Neurology · doi:10.1002/ana.410440324 · Cited by 686 · cited 1×
“…is characterized neuropathologically by glial cytoplasmic inclusions (GCIs) of -synuclein ( syn), primarily in oligodendrocytes (Arima et al., 1998; Tu et al., 1998; Wakabayashi et al., 1998a,b) unlike other -synucleinopathies, such as Parkinson’s disease (PD) and dementia with Lewy bodies, which…”
BackgroundIRANMANESH, A., LIZARRALDE, G., & VELDHUIS, J. D. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-5-1081 · Cited by 672
α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy
Wakabayashi, K., Yoshimoto, M., Tsuji, S., & Takahashi, H. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00407-8 · Cited by 643
Impaired growth hormone secretion in the adult population: relation to age and adiposity.
Rudman, D. R., Kutner, M., Rogers, C. M., Lubin, M., Fleming, G. A., & Bain, R. P. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110164 · Cited by 641
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia‐Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 589
Cited by
Sorted by citations
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Wong, Y. C., & Krainc, D. (2017) · Nature Medicine · doi:10.1038/nm.4269 · Cited by 897
Tsunemi, T., Ashe, T. D., Morrison, B. E., Epilepsia, K. S., Au, J., Vázquez‐Roque, R. A., Lazarowski, E. R., Damian, V. A., Masliah, E., & Spada, A. R. L. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003799 · Cited by 456
Self-citationGlia: Initiators and progressors of pathology in Parkinson's disease
Halliday, G. M., & Stevens, C. H. (2011) · Movement Disorders · doi:10.1002/mds.23455 · Cited by 436
Games, D., Valera, E., Spencer, B. J., Rockenstein, E. M., Mante, M., Adame, A., Patrick, C., Ubhi, K. K., Nuber, S., Sacayon, P., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.5314-13.2014 · Cited by 329
Self-citationInsulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification?
Bassil, F., Fernagut, P., Bézard, E., & Meissner, W. G. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.005 · Cited by 323
Benskey, M. J., Perez, R. G., & Manfredsson, F. P. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13570 · Cited by 257
Mandler, M., Valera, E., Rockenstein, E. M., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O. W., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 239
Self-citationMultiple System Atrophy: An Oligodendroglioneural Synucleinopathy
Jellinger, K. A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170397 · Cited by 218
Glia and alpha-synuclein in neurodegeneration: A complex interaction
Brück, D., Wenning, G. K., Stefanova, N., & Fellner, L. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.003 · Cited by 213
Neuropathology of multiple system atrophy: New thoughts about pathogenesis
Jellinger, K. A. (2014) · Movement Disorders · doi:10.1002/mds.26052 · Cited by 181
Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts
Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0833-z · Cited by 162
Multiple system atrophy: a clinical and neuropathological perspective
Ubhi, K. K., Low, P. A., & Masliah, E. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.08.003 · Cited by 162
Self-citationOligodendroglia and Myelin in Neurodegenerative Diseases: More Than Just Bystanders?
Ettle, B., Schlachetzki, J. C. M., & Winkler, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9205-3 · Cited by 160
Nuber, S., Harmuth, F., Kohl, Z., Adame, A., Trejo, M., Schönig, K., Zimmermann, F., Bauer, C. C., Casadei, N., Giel, C., et al. (2013) · Brain · doi:10.1093/brain/aws358 · Cited by 161
Self-citationMesenchymal Stromal Cell Therapies for Neurodegenerative Diseases
Staff, N. P., Jones, D. T., & Singer, W. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.001 · Cited by 150
Mandler, M., Valera, E., Rockenstein, E. M., Mante, M., Weninger, H., Patrick, C., Adame, A., Schmidhuber, S. M., Santic, R., Schneeberger, A., et al. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0008-9 · Cited by 150
Self-citationGDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease
Azevedo, M. D., Sander, S., & Tenenbaum, L. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020456 · Cited by 146
Immunotherapy for neurodegenerative diseases: Focus on α-synucleinopathies
Valera, E., & Masliah, E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.013 · Cited by 132
Self-citationInsulin resistance and exendin-4 treatment for multiple system atrophy
Bassil, F., Canron, M., Vital, A., Bézard, E., Li, Y., Greig, N. H., Gulyani, S., Kapogiannis, D., Fernagut, P., & Meissner, W. G. (2017) · Brain · doi:10.1093/brain/awx044 · Cited by 108
T cell infiltration in both human multiple system atrophy and a novel mouse model of the disease
Williams, G. P., Marmion, D. J., Schonhoff, A. M., Jurkuvenaite, A., Won, W.-J., Standaert, D. G., Kordower, J. H., & Harms, A. S. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02126-w · Cited by 102
Benskey, M. J., Sellnow, R. C., Sandoval, I. M., Sortwell, C. E., Lipton, J. W., & Manfredsson, F. P. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00036 · Cited by 102
Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy
Singer, W., Dietz, A. B., Zeller, A., Gehrking, T. L., Schmelzer, J. D., Schmeichel, A. M., Gehrking, J. A., Suarez, M. D., Sletten, D. M., Minota, K., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007720 · Cited by 96
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 97
Self-citationAnimal models of multiple system atrophy
Stefanova, N., & Wenning, G. K. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0266-6 · Cited by 94
Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives
Compagnoni, G. M., & Fonzo, A. D. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0730-6 · Cited by 93
Insulin-like growth factors in the brain and their potential clinical implications
Benarroch, E. E. (2012) · Neurology · doi:10.1212/wnl.0b013e3182752eef · Cited by 92
α-Synuclein impairs oligodendrocyte progenitor maturation in multiple system atrophy
May, V. E. L., Ettle, B., Poehler, A.-M., Nuber, S., Ubhi, K. K., Rockenstein, E. M., Winner, B., Wegner, M., Masliah, E., & Winkler, J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.028 · Cited by 85
Self-citationUbhi, K. K., Inglis, C. A., Mante, M., Patrick, C., Adame, A., Spencer, B. J., Rockenstein, E. M., May, V. E. L., Winkler, J., & Masliah, E. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.01.008 · Cited by 87
Self-citationSekar, S., Ranju, V., Kalaivani, P., Priya, R. J., Sumathy, H., Sunil, A. G., & Chidambaram, S. B. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.05.025 · Cited by 78
Valera, E., Ubhi, K. K., Mante, M., Rockenstein, E. M., & Masliah, E. (2013) · Glia · doi:10.1002/glia.22610 · Cited by 79
Self-citationWidespread micro RNA dysregulation in multiple system atrophy – disease‐related alteration in miR‐96
Ubhi, K. K., Rockenstein, E. M., Kragh, C. L., Inglis, C. A., Spencer, B. J., Michael, S. A., Mante, M., Adame, A., Galasko, D., & Masliah, E. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12444 · Cited by 78
Self-citationAn emerging role of dysfunctional axon-oligodendrocyte coupling in neurodegenerative diseases
Mot, A. I., Depp, C., & Nave, K. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.4/amot · Cited by 72
Rydbirk, R., Elfving, B., Andersen, M. D., Langbøl, M. A., Folke, J., Winge, K., Pakkenberg, B., Brudek, T., & Aznar, S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.07.014 · Cited by 71
Oligodendroglia and neurotrophic factors in neurodegeneration
Bankston, A. N., Mandler, M. D., & Feng, Y. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1321-3 · Cited by 76
Multiple system atrophy: pathogenic mechanisms and biomarkers
Jellinger, K. A., & Wenning, G. K. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1545-2 · Cited by 70
Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions
Kaji, S., Maki, T., Ishimoto, T., Yamakado, H., & Takahashi, R. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-0185-5 · Cited by 71
The Role of Glia in Alpha-Synucleinopathies
Fellner, L., & Stefanova, N. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8340-3 · Cited by 69
Refolo, V., Bez, F., Polissidis, A., Kuzdas-Wood, D., Sturm, E., Kamaratou, M., Poewe, W., Stefanis, L., Angela Cenci, M., Romero-Ramos, M., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0504-y · Cited by 67
Multiple system atrophy of the cerebellar type: Clinical state of the art
Lin, D. J., Hermann, K. L., & Schmahmann, J. D. (2014) · Movement Disorders · doi:10.1002/mds.25847 · Cited by 67
Glial cells involvement in spinal muscular atrophy: Could SMA be a neuroinflammatory disease?
Abati, E., Citterio, G., Bresolin, N., Comi, G. P., & Corti, S. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104870 · Cited by 72
Valera, E., Mante, M., Anderson, S., Rockenstein, E. M., & Masliah, E. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0320-x · Cited by 67
Self-citationSpencer, B. J., Potkar, R., Metcalf, J., Thrin, I., Adame, A., Rockenstein, E. M., & Masliah, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.678185 · Cited by 66
Self-citationZhao, J., Cheng, Y., Fan, W., Yang, C., Ye, S., Cui, W., Wei, W., Lao, L., Cai, J., Han, Y., et al. (2014) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12334 · Cited by 65
Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms
Stefanova, N., & Wenning, G. K. (2023) · Nature reviews. Neuroscience · doi:10.1038/s41583-023-00697-7 · Cited by 62
Ferrer, I. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.07.004 · Cited by 65
The neuropathology of multiple system atrophy and its therapeutic implications
Valera, E., & Masliah, E. (2017) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.11.002 · Cited by 62
Self-citationWang, Q., Shen, Z., Zhang, S., Sun, Y., Zheng, F., & Li, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1022053 · Cited by 61
Nakamura, K., Mori, F., Kon, T., Tanji, K., Miki, Y., Tomiyama, M., Kurotaki, H., Toyoshima, Y., Kakita, A., Takahashi, H., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0208-0 · Cited by 61
Gliotoxicity and Glioprotection: the Dual Role of Glial Cells
Quincozes‐Santos, A., Santos, C. L., Almeida, R. R. D. S., da Silva, A., Thomaz, N. K., Costa, N. L. F., Weber, F. B., Schmitz, I., Medeiros, L. S., Medeiros, L., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02574-9 · Cited by 64
Mandel, R. J., Marmion, D. J., Kirik, D., Chu, Y., Heindel, C., McCown, T., Gray, S. J., & Kordower, J. H. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0451-7 · Cited by 55
Review: Multiple system atrophy: emerging targets for interventional therapies
Stefanova, N., & Wenning, G. K. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12304 · Cited by 52
Serine 421 regulates mutant huntingtin toxicity and clearance in mice
Kratter, I. H., Zahed, H., Lau, A., Tsvetkov, A. S., Daub, A. C., Weiberth, K. F., Gu, X., Saudou, F., Humbert, S., Yang, X. W., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci80339 · Cited by 54
Self-citationKoller, E. J., Brooks, M., Golde, T. E., Giasson, B. I., & Chakrabarty, P. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0142-z · Cited by 55
Jellinger, K. A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02028-6 · Cited by 58
The Role of Neuroinflammation and Network Anomalies in Drug-Resistant Epilepsy
Shi, J., Xie, J., Li, Z., He, X., Wei, P., Sander, J. W. A. S., & Zhao, G. (2025) · Neuroscience Bulletin · doi:10.1007/s12264-025-01348-w · Cited by 55
Lin, Y., Pang, X., Huang, G.-C., Jamison, S., Fang, J., Harding, H., Ron, D., & Lin, W.-S. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1373-14.2014 · Cited by 49
Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model
Amschl, D., Neddens, J., Havas, D., Flunkert, S., Rabl, R., Römer, H., Rockenstein, E. M., Masliah, E., Windisch, M., & Hutter‐Paier, B. (2013) · BMC Neuroscience · doi:10.1186/1471-2202-14-6 · Cited by 52
Self-citationNeurons and Glia Interplay in α-Synucleinopathies
Mavroeidi, P., & Xilouri, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094994 · Cited by 55
Spencer, B. J., Valera, E., Rockenstein, E. M., Trejo, M., Adame, A., & Masliah, E. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0043-6 · Cited by 48
Self-citationExtracellular Alpha-Synuclein: Mechanisms for Glial Cell Internalization and Activation
Chavarría, C., Ivagnes, R., & Souza, J. M. (2022) · Biomolecules · doi:10.3390/biom12050655 · Cited by 47
Exploring Myelin Dysfunction in Multiple System Atrophy
Wong, J. H., Halliday, G. M., & Kim, W. S. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.4.337 · Cited by 45
Spencer, B. J., Trinh, I., Rockenstein, E. M., Mante, M., Florio, J. B., Adame, A., El‐Agnaf, O. M. A., Kim, C., Masliah, E., & Rissman, R. A. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.001 · Cited by 48
Self-citationSpencer, B. J., Williams, S. M., Rockenstein, E. M., Valera, E., Xin, W., Mante, M., Florio, J. B., Adame, A., Masliah, E., & Sierks, M. R. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.321 · Cited by 43
Self-citationRetractedTargeting α‐synuclein: Therapeutic options
Dehay, B., Decressac, M., Bourdenx, M., Guadagnino, I., Fernagut, P., Tamburrino, A., Bassil, F., Meissner, W. G., & Bézard, E. (2016) · Movement Disorders · doi:10.1002/mds.26568 · Cited by 44
Towards translational therapies for multiple system atrophy
Kuzdas-Wood, D., Stefanova, N., Jellinger, K. A., Seppi, K., Schlossmacher, M. G., Poewe, W. H., & Wenning, G. K. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.02.007 · Cited by 39
Nuber, S., Tadros, D., Fields, J. A., Overk, C., Ettle, B., Kosberg, K. A., Mante, M., Rockenstein, E. M., Trejo, M., & Masliah, E. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1255-5 · Cited by 38
Self-citationThe PROMESA study group, Levin, J., Maaß, S., Schuberth, M., Respondek, G., Paul, F., Mansmann, U., Oertel, W. H., Lorenzl, S., Krismer, F., et al. (2016) · Journal of Neural Transmission · doi:10.1007/s00702-016-1507-8 · Cited by 38
Animal models of multiple system atrophy
Fernagut, P., & Tison, F. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.044 · Cited by 39
NGF and nitrosative stress in patients with Huntington's disease
Tasset, I., Sánchez‐López, F., Agüera, E., Fernández‐Bolaños, R., Sánchez, F. M., Cruz-Guerrero, A., Gascón-Luna, F., & Túnez, I. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.12.014 · Cited by 36
Segura‐Ulate, I., Yang, B. C., Vargas‐Medrano, J., & Perez, R. G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.028 · Cited by 36
Ziemka‐Nałęcz, M., Janowska, J., Strojek, L., Jaworska, J., Zalewska, T., Frontczak‐Baniewicz, M., & Sypecka, J. (2017) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13309 · Cited by 36
Fernagut, P. O., Meissner, W. G., Biran, M., Fantin, M., Bassil, F., Franconi, J. M., & Tison, F. (2014) · Synapse · doi:10.1002/syn.21719 · Cited by 35
Rockenstein, E. M., Overk, C., Ubhi, K. K., Mante, M., Patrick, C., Adame, A., Bisquert, A., Trejo, M., Spencer, B. J., & Masliah, E. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121570 · Cited by 34
Self-citationRetractedOligodendrocytes in neurodegenerative diseases
Liu, Y., & Zhou, J. (2013) · Frontiers in Biology · doi:10.1007/s11515-013-1260-4 · Cited by 36
New insights into atypical parkinsonism
Wenning, G. K., Krismer, F., & Poewe, W. H. (2011) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283480569 · Cited by 32
Cross-examining candidate genes implicated in multiple system atrophy
Katzeff, J. S., Phan, K., Purushothuman, S., Halliday, G. M., & Kim, W. S. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0769-4 · Cited by 32
Kinoshita, C., Aoyama, K., & Nakaki, T. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.11.023 · Cited by 32
Rockenstein, E. M., Ubhi, K. K., Inglis, C. A., Mante, M., Patrick, C., Adame, A., & Masliah, E. (2012) · Neuroreport · doi:10.1097/wnr.0b013e3283509842 · Cited by 31
Self-citationFAS-Dependent Cell Death in α-Synuclein Transgenic Oligodendrocyte Models of Multiple System Atrophy
Kragh, C. L., Fillon, G., Gysbers, A. M., Hansen, H. D., Neumann, M., Richter‐Landsberg, C., Haass, C., Zalc, B., Lubetzki, C., Gai, W.-P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055243 · Cited by 31
Models of multiple system atrophy
Lee, H.-J., Ricarte, D., Ortiz, D. M., & Lee, S. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0346-8 · Cited by 33
Mandler, M., Rockenstein, E. M., Overk, C., Mante, M., Florio, J. B., Adame, A., Kim, C., Santic, R., Schneeberger, A., Mattner, F., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.002 · Cited by 29
Self-citationHuang, M., Xu, L., Liu, J., Huang, P., Tan, Y., & Chen, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.828457 · Cited by 31
Sypecka, J., & Sarnowska, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8549-9 · Cited by 27
Glia: an emerging target for neurological disease therapy
Almad, A. A., & Maragakis, N. J. (2012) · Stem Cell Research & Therapy · doi:10.1186/scrt128 · Cited by 27
Zhou, W., Xia, S., Wang, C., Yang, Q., Verkhratsky, A., & Niu, J. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07893-6 · Cited by 31
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Fouka, M., Mavroeidi, P., Tsaka, G., & Xilouri, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.559791 · Cited by 27
Marmion, D. J., Rutkowski, A., Chatterjee, D., Hiller, B. M., Werner, M. H., Bézard, E., Kirik, D., McCown, T. J., Gray, S. J., & Kordower, J. H. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105184 · Cited by 26
An update on the cerebellar subtype of multiple system atrophy
Ciolli, L., Krismer, F., Nicoletti, F., & Wenning, G. K. (2014) · Cerebellum & Ataxias · doi:10.1186/s40673-014-0014-7 · Cited by 27
Vidal-Martínez, G., Segura‐Ulate, I., Yang, B. C., Diaz-Pacheco, V., Barragan, J. A., Esquivel, J. D.-L., Chaparro, S. A., Vargas‐Medrano, J., & Perez, R. G. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113120 · Cited by 26
Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
Cignarelli, A., Genchi, V. A., Le Grazie, G., Caruso, I., Marrano, N., Biondi, G., D’Oria, R., Sorice, G. P., Natalicchio, A., Perrini, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.846903 · Cited by 24
Vallelunga, A., Iannitti, T., Capece, S., Somma, G., Russillo, M. C., Foubert‐Samier, A., Laurens, B., Sibon, I., Meissner, W. G., Barone, P., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.632891 · Cited by 24
Novel therapeutic approaches in multiple system atrophy
Palma, J.-A., & Kaufmann, H. (2015) · Clinical Autonomic Research · doi:10.1007/s10286-014-0249-7 · Cited by 24
Sypecka, J., Sarnowska, A., Szabłowska‐Gadomska, I., Lukomska, B., & Domańska‐Janik, K. (2013) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2013-1926 · Cited by 24
Oligodendrocyte-specific ATF4 inactivation does not influence the development of EAE
Yue, Y., Stanojlović, M., Lin, Y., Karsenty, G., & Lin, W. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1415-6 · Cited by 23
Intact Olfaction in a Mouse Model of Multiple System Atrophy
Krismer, F., Wenning, G. K., Li, Y., Poewe, W. H., & Stefanova, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064625 · Cited by 22
Janowska, J., & Sypecka, J. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0647-7 · Cited by 24
Fiandaca, M. S., Lonser, R. R., Elder, J. B., Ząbek, M., & Bankiewicz, K. S. (2020) · Neurologia i Neurochirurgia Polska · doi:10.5603/pjnns.a2020.0046 · Cited by 20
Multiple system atrophy - a clinicopathological update
Jellinger, K. A. (2020) · Free Neuropathology · doi:10.17879/freeneuropathology-2020-2813 · Cited by 20
Multiple system atrophy: experimental models and reality
Overk, C., Rockenstein, E. M., Valera, E., Stefanova, N., Wenning, G. K., & Masliah, E. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1772-0 · Cited by 23
Self-citationMSA: From basic mechanisms to experimental therapeutics
Heras‐Garvin, A., & Stefanova, N. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.01.010 · Cited by 21
Metadata
- Authors
- Ubhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C., Whitney, K., & Masliah, E.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Masliah, Eliezer
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2010-05-05
- Volume
- 30
- Issue
- 18
- Pages
- 6236-6246
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC2896284
- OpenAlex
- W2004154235
- Cited by
- 147
- References
- 74
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 8 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 8 · 2017: 14 · 2016: 9 · 2015: 10 · 2014: 17 · 2013: 17 · 2012: 10
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AG‐022074, AG‐18440, NS044233, AG10435)
- National Institute on Aging (P01AG010435, R37AG018440, R01AG018440, AG022074, AG 18440, P01AG022074, AG10435)
- National Institute of Neurological Disorders and Stroke (P01NS044233, NS-044233)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- multiple system atrophy, alpha-synuclein, oligodendrocytes, neurotrophic factors, glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, insulin-like growth factor I, basic fibroblast growth factor, neurodegeneration, striatonigral degeneration, transgenic mouse model, intracerebroventricular infusion, white matter
- MeSH terms
- Aged, Animals, Behavior, Animal, Brain, Disease Models, Animal, Female, Humans, Injections, Intraventricular, Male, Mice, Transgenic, Nerve Degeneration, Nerve Fibers, Myelinated, Nerve Growth Factors, Neurons, Oligodendroglia, Promoter Regions, Genetic, Mice, Knockout, Multiple System Atrophy, Glial Cell Line-Derived Neurotrophic Factor, Mice, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
